Cited by 1,544Bone health and osteoporosis researchBone health and treatmentsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Open access

Saag, Kenneth G., Petersen, Jeffrey, Brandi, Maria Luisa, Karaplis, Andrew C., Lorentzon, Mattias, Thomas, Thierry, Maddox, Judy, Fan, Michelle, Meisner, Paul D., Grauer, Andreas·2017·New England Journal of Medicine

DOI 10.1056/nejmoa1708322

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1708322

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citation
Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis
Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citation
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citation
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011

Flagged first, then by citations

Show all 31 references

Sorted by citations

Items 701–800 of 1,000

Teriparatide in postmenopausal osteoporosis: uncovering novel insights into efficacy and safety compared to other treatments – a systematic review and meta-analysis
Vithran, D. T. A., Essien, A. E., Rahmati, M., Opoku, M., Yon, D. K., Sánchez, G. F. L., Koyanagi, A., Smith, L., Shin, J. I., Xiao, W., et al. (2024) · EFORT Open Reviews · doi:10.1530/eor-23-0205 · Cited by 10
Comparative effectiveness of romosozumab versus teriparatide for fracture prevention: A new-user, active comparator design
Tominaga, R., Ikenoue, T., Ishii, R., Niihata, K., Aita, T., Okuda, T., Shimizu, S., Kurita, N., & Taguri, M. (2025) · Bone · doi:10.1016/j.bone.2025.117523 · Cited by 10
Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease
Buxbaum, N. P., Robinson, C., Sinaii, N., Ling, A. L., Curtis, L. M., Pavletic, S. Z., Baird, K., & Lodish, M. B. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.02.019 · Cited by 10
Evidence for Ongoing Modeling-Based Bone Formation in Human Femoral Head Trabeculae via Forming Minimodeling Structures: A Study in Patients with Fractures and Arthritis
Sano, H., Kondo, N., Shimakura, T., Fujisawa, J., Kijima, Y., Kanai, T., Poole, K. E. S., Yamamoto, N., Takahashi, H. E., & Endo, N. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00088 · Cited by 10
Combination therapy in the Col1a2G610C mouse model of Osteogenesis Imperfecta reveals an additive effect of enhancing LRP5 signaling and inhibiting TGFβ signaling on trabecular bone but not on cortical bone
Kaupp, S. M., Horan, D. J., Lim, K., Feldman, H. A., Robling, A. G., Warman, M. L., & Jacobsen, C. M. (2019) · Bone · doi:10.1016/j.bone.2019.115084 · Cited by 10
Bisphosphonates: Mechanisms of Action and Role in Osteoporosis Therapy
Santora, A. C., & Sharma, A. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_14 · Cited by 12
Enhancement of osteoblast differentiation using poly(ethylene sodium phosphate)
Otaka, A., Kiyono, K., & Iwasaki, Y. (2020) · Materialia · doi:10.1016/j.mtla.2020.100977 · Cited by 10
Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan
TANAKA, M., Idei, M., Sakaguchi, H., Kato, R., Sato, D., Sawanobori, K., Kawarasaki, S., Hata, T., Yoshizaki, A., Nakamura, M., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14749 · Cited by 10
Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis and Metabolic Bone Diseases
Lewiecki, E. M., Anderson, P. A., Bilezikian, J. P., Binkley, N., Cheung, A. M., Imel, E. A., Krueger, D. C., McClung, M. R., Miller, P. D., & Rothman, M. S. (2021) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2021.10.001 · Cited by 10
New Osteoporosis Treatment Means New Bone Formation
Blakely, K. K., & Johnson, C. (2019) · Nursing for Women s Health · doi:10.1016/j.nwh.2019.11.002 · Cited by 10
Modified Quinoxaline‐Fused Oleanolic Acid Derivatives as Inhibitors of Osteoclastogenesis and Potential Agent in Anti‐Osteoporosis
Zhang, Y., Shen, Q., Zhu, M., Wang, J., Du, Y., Wu, J., & Li, J. (2020) · ChemistrySelect · doi:10.1002/slct.201904521 · Cited by 10
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
Cejka, D. (2021) · Metabolites · doi:10.3390/metabo11110770 · Cited by 10
Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications
Bover, J., Ureña, P., Láiz, A. M., Torregrosa, J., Rodríguez-García, M., Castro-Alonso, C., Górriz, J. L., Benito, S., López‐Báez, V., Cora, M. J. L., et al. (2019) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.10.008 · Cited by 10
The WNT/β-catenin system in chronic kidney disease-mineral bone disorder syndrome
Zhang, L., Adu, I. K., Zhang, H., & Wang, J. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03569-2 · Cited by 9
Monthly treatment with romosozumab for 1 year increases bone mineral at the hip, but not the knee, in women with chronic spinal cord injury
Crack, L. E., Simonian, N., Schnitzer, T. J., & Edwards, W. B. (2024) · JBMR Plus · doi:10.1093/jbmrpl/ziae077 · Cited by 10
‘Bone Health—Across a Woman's Lifespan’
Stokes, G., Herath, M., Samad, N., Trinh, A., & Milat, F. (2025) · Clinical Endocrinology · doi:10.1111/cen.15203 · Cited by 9
Early administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study
Piasentier, A., Fanti, A., Birtolo, M. F., Vena, W., Colle, R., Gentile, L. M. S., Jaafar, S., Bossi, A. C., Lania, A. G., & Mazziotti, G. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02542-3 · Cited by 9
Role of Sclerostin in Cardiovascular System
Zhang, N., Wang, L., Li, X., Yang, X., Tao, X., Jiang, H., Yu, Y., Liu, J., Yu, S., Ma, Y., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104552 · Cited by 10
A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
Sobue, Y., Kosugiyama, H., Asai, S., Ogawa, Y., Yoneda, M., Maruyama, K., Kaneko, M., Kobayakawa, T., Terabe, K., Suzuki, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-05187-7 · Cited by 9
Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study
Vilaça, T., Lui, L., Schini, M., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Black, D. M., Bouxsein, M., & Eastell, R. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf100 · Cited by 9
A systematic review and meta-analysis of sequential treatment strategies for osteoporosis
Nayak, S., & Greenspan, S. L. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07717-5 · Cited by 9
Odanacatib: the best osteoporosis treatment we never had?
Statham, L., & Aspray, T. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30348-1 · Cited by 9
Treatment of bone fragility in patients with diabetes: antiresorptive versus anabolic?
Shah, M., Appuswamy, A. V., Rao, S. D., & Dhaliwal, R. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000645 · Cited by 9
Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual‐Energy X‐Ray Absorptiometry ( DXA)
Winzenrieth, R., Kostenuik, P. J., Boxberger, J. I., Wang, Y., & Humbert, L. (2022) · JBMR Plus · doi:10.1002/jbm4.10612 · Cited by 9
A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab
Chen, Z., Li, M., Li, S., Li, Y., Wu, J., Qiu, K., Yu, X., Huang, L. C., & Chen, G. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2130891 · Cited by 9
Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients
Oue, T., Shimizu, T., Asano, T., Shimodan, S., Ishizu, H., Arita, K., & Iwasaki, N. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01079-y · Cited by 9
Sustained release of a highly specific GSK3β inhibitor SB216763 in the PCL scaffold creates an osteogenic niche for osteogenesis, anti-adipogenesis, and potential angiogenesis
Gong, W., Li, M., Zhao, L., Wang, P., Wang, X., Wang, B., Liu, X., & Tu, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1215233 · Cited by 9
Methodological guidance for the use of real-world data to measure exposure and utilization patterns of osteoporosis medications
Hayes, K. N., Cadarette, S. M., & Burden, A. M. (2023) · Bone Reports · doi:10.1016/j.bonr.2023.101730 · Cited by 9
Discovery of the small molecular inhibitors against sclerostin loop3 as potential anti-osteoporosis agents by structural based virtual screening and molecular design
Yu, S., Huang, W., Zhang, H., Guo, Y., Zhang, B., Zhang, G., & Lei, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116414 · Cited by 9
Single Dose of SHR-1222, a Sclerostin Monoclonal Antibody, in Healthy Men and Postmenopausal Women With Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase I Study
Dai, Z., Fang, P., Yan, X., Zhu, R., Feng, Q., Yan, Q., Yang, L., Fan, X., Xie, Y., Zhuang, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770073 · Cited by 9
Antitumor Effect of Sclerostin against Osteosarcoma
Ideta, H., Yoshida, K., Okamoto, M., Sasaki, J., Kito, M., Aoki, K., Yoshimura, Y., Suzuki, S.-I., Tanaka, A., Takazawa, A., et al. (2021) · Cancers · doi:10.3390/cancers13236015 · Cited by 10
Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis
Su, Y., Wang, W., Liu, F., Cai, Y., Li, N., Li, H., Li, G., & Ma, L. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-998 · Cited by 9
Current Treatment of Osteoporosis
Nallasivan, S. (2018) · Indian Journal of Rheumatology · doi:10.4103/injr.injr_74_18 · Cited by 9
The role of antibody delivery formation in cancer therapy
Qi, T., Shi, Y., Huang, Y., Fu, X., Qiu, S., Sun, Q., & Lin, G. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1728537 · Cited by 9
Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells
Giollo, A., Rossini, M., Gatti, D., Adami, G., Orsolini, G., Fassio, A., Caimmi, C., Idolazzi, L., & Viapiana, O. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3660 · Cited by 9
Comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics”
Hólm, H., Sulem, P., Tragante, V., Þorsteinsdóttir, U., Gudbjartsson, D. F., & Stefánsson, K. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe8497 · Cited by 9
Guidelines for fracture risk assessment and management of osteoporosis in postmenopausal women and men above the age of 50 in Qatar
Alam, F., Alsaed, O. S., Abdulla, N., Abdulmomen, I., Lutf, A. Q. A., & Emadi, S. A. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01389-0 · Cited by 10
Romosozumab rescues impaired bone mass and strength in a murine model of diabetic kidney disease
Kohler, R. K., Segvich, D. M., Reul, O. N., Metzger, C. E., Allen, M. R., & Wallace, J. M. (2024) · Bone Reports · doi:10.1016/j.bonr.2024.101774 · Cited by 8
FOXO1-mTOR pathway in vascular pericyte regulates the formation of type H vessels to control bone metabolism
Cheng, C., Deng, M., Cheng, C., Wu, H., Wang, Y., Lu, M., Yao, Z., Li, K., Zhang, X., & Yu, B. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.08.010 · Cited by 8
Diagnosis and Management of Atypical Femoral Fractures and Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis
Alnajmi, R. A. Y., Ali, D. S., & Khan, A. A. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.08.007 · Cited by 8
Effect of Vitamin D3, Omega-3 Fatty Acids, and Exercise on Serum Sclerostin Levels and Bone Turnover Markers
Tsourdi, E. A., Gängler, S., Kistler-Fischbacher, M., Rauner, M., Dawson-Hughes, B. F., Orav, E. J., Tsai, L.-T., Lang, W., Kanis, J. А., Theiler, R., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae859 · Cited by 8
Efficacy and safety of sequential therapy for primary osteoporosis with bone formation promoters followed by bone resorption inhibitors: a meta-analysis
Liu, Y., Liu, X., Wu, Y., & Luo, T. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05545-1 · Cited by 8
Optimisation of romosozumab plus denosumab sequential treatments against postmenopausal osteoporosis. Insights from in silico simulations
Ruiz-Lozano, R., Calvo‐Gallego, J. L., Pivonka, P., & Martínez‐Reina, J. (2025) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-024-01900-z · Cited by 8
Efficacy and safety of romosozumab in patients with chronic kidney disease and osteoporosis: a narrative review
Abdalbary, M., Amin, A. M., Elaraby, A. R., & Hassan, A. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07707-7 · Cited by 8
Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study
Tsai, S. H. L., Chen, Y. H., Yang, C., Lee, C., Chen, C.-H., Huang, T.-J., Wu, M., Huang, H.-E., & James, W. C. (2026) · Osteoporosis International · doi:10.1007/s00198-026-07968-w · Cited by 8
Secondary fracture prevention: Drug treatment, fall prevention and nutrition requirements
Geusens, P., Lems, W. F., Bours, S., & van den Bergh, J. P. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.04.005 · Cited by 8
Novel bone-targeted parathyroid hormone-related peptide antagonists inhibit breast cancer bone metastases
Ponnapakkam, T., Anbalagan, M., Stratford, R. E., Rowan, B. G., & Gensure, R. C. (2021) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001051 · Cited by 8
Romosozumab used to treat a patient with cystic fibrosis-related osteoporosis
Crow, H., Graves, L., & Anabtawi, A. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.04.018 · Cited by 8
Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet
Pereira, L., Meng, C., Amoedo, M. A. G., Mendes, M. T. D. S. C. P. F., Marques, M. A. M. P., Frazão, J. M., & Weigert, A. L. L. (2022) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2022.11.014 · Cited by 8
Sclerostin deficiency effectively promotes bone morphogenetic protein‐2‐induced ectopic bone formation
Nakamura, K., Koide, M., Kobayashi, Y., Yamashita, T., Matsushita, M., Yasuda, H., Ishihara, Y., Yoshinari, N., & Udagawa, N. (2023) · Journal of Periodontal Research · doi:10.1111/jre.13134 · Cited by 8
Anti-resorptive therapy in the osteometabolic patient affected by periodontitis. A joint position paper of the Italian Society of Orthopaedics and Traumatology (SIOT) and the Italian Society of Periodontology and Implantology (SIdP)
Landi, L., Leali, P. T., Barbato, L., Carrassi, A., Discepoli, N., Muti, P. C., Oteri, G., Rigoni, M., Romanini, E., Ruggiero, C., et al. (2023) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-023-00713-7 · Cited by 8
Self-citation
Antiosteoporosis medications and cardiovascular disease: a population-based nationwide nested case–control study
Tsai, W.-H., Sung, F., Muo, C., Tsai, M.-C., & Wu, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1220174 · Cited by 8
Improving Kidney Disease Care: One Giant Leap for Nephrology
Provenzano, M., Hu, L., Tringali, E., Senatore, M., Talarico, R., Dio, M. D., Ruotolo, C., Manna, G. L., Garofalo, C., & Zaza, G. (2024) · Biomedicines · doi:10.3390/biomedicines12040828 · Cited by 8
Aterosclerosis, calcificación vascular y osteoporosis
Valero, C., & Macías, J. G. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2024.07.004 · Cited by 8
Breaking Down Bone Disease in People Living with HIV: Pathophysiology, Diagnosis, and Treatment
Hasenmajer, V., D'Addario, N. F., Bonaventura, I., Sada, V., Nardi, C., Jannini, E. A., d’Ettorre, G., Mastroianni, C. M., & Gianfrilli, D. (2024) · Advances in experimental medicine and biology · doi:10.1007/5584_2024_831 · Cited by 9
Treatment of osteoporosis in the solid organ transplant recipient: an organ-based approach
Kurnool, S., Shah, N., & Ekanayake, P. S. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251347351 · Cited by 8
A Novel Oral Anti-osteoporosis Drug with Osteogenesis-promoting Effects via Osteoblast Differentiation
Kitao, T., Ito, Y., Fukui, M., Yamamoto, M., Shoji, Y., Takeda, S., & Shirahase, H. (2018) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00154-2 · Cited by 8
Bone formation around unstable implants is enhanced by a WNT protein therapeutic in a preclinical in vivo model
Coyac, B. R., Leahy, B., Li, Z., Salvi, G., Yin, X., Brunski, J., & Helms, J. A. (2020) · Clinical Oral Implants Research · doi:10.1111/clr.13659 · Cited by 8
A pragmatic proposal for triaging DXA testing during the COVID-19 global pandemic
Sapkota, H. R., Nune, A., Bateman, J., & Venkatachalam, S. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05722-4 · Cited by 8
Metabolism and Endocrine Disorders: What Wnt Wrong?
Franco, C. N., Noe, M. M., & Albrecht, L. V. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.887037 · Cited by 8
Osteoporosis Management
DeSapri, K. T., & Batur, P. (2019) · Journal of Women s Health · doi:10.1089/jwh.2019.8195 · Cited by 8
Diagnose und Therapie der Osteoporose bei Patienten mit chronischer Niereninsuffizienz
Cejka, D., Wakolbinger, R., Zitt, E., Fahrleitner‐Pammer, A., Amrein, K., Dimai, H. P., & Muschitz, C. (2022) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-022-00989-0 · Cited by 8
Messages from the Mineral: How Bone Cells Communicate with Other Tissues
Plotkin, L. I., Sanz, N., & Brun, L. R. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01091-2 · Cited by 9
Interactions between Sclerostin and Glycosaminoglycans
Zhang, F., Zhao, J., Liu, X., & Linhardt, R. J. (2019) · Glycoconjugate Journal · doi:10.1007/s10719-019-09900-3 · Cited by 8
Amniotic fluid volume at 41 weeks and infant outcome.
Lam, H., Leung, W.-C., Lee, C.-P., & Lao, T. T.-H. (2006) · PubMed · Cited by 8
Cardiovascular Safety and Romosozumab—The Plot Thickens
Farr, J. N. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae313 · Cited by 8
The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
Fassio, A., Gatti, D., Biffi, A., Ronco, R., Porcu, G., Adami, G., Alvaro, R., Bogini, R., Caputi, A. P., Cianferotti, L., et al. (2024) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x241234584 · Cited by 7
Self-citation
Chronic pancreatitis-associated metabolic bone diseases: epidemiology, mechanisms, and clinical advances
Wang, T., Xiong, K., He, Y., Feng, B., Guo, L., Gu, J., Zhang, M., Wang, H., & Wu, X. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00113.2024 · Cited by 7
Extending the Therapeutic Potential: Romosozumab in Osteoporosis Management
Liu, L. Q., Clifton-Bligh, R. J., Girgis, C. M., & Gild, M. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae160 · Cited by 7
Inflammaging-Driven Osteoporosis: Is a Galectin-Targeted Approach Needed?
Russo, M., Lepre, C. C., Itro, A., Martin, G., Conza, G., Trotta, M. C., Puticiu, M. I., Hermenean, A. O., Gimigliano, F., D’Amico, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136473 · Cited by 7
Romosozumab in postmenopausal women with smoldering multiple myeloma: a prospective 12-mo study
Diz-Lopes, M., Pollastri, F., Mastropaolo, F., Somma, R., Tugnolli, M., Pasetto, E., Benini, C., Messina, V., Gatti, D., Viapiana, O., et al. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf144 · Cited by 7
ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study
Adami, G., Bartezaghi, M., Montanari, F., Piccinelli, A., Pollastri, F., Mastropaolo, F., Giorgio, F., Benini, C., Fassio, A., Rossini, M., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07722-8 · Cited by 7
Bone mineral density response to romosozumab in post-menopausal women: A prospective observational real-world study
Gielen, E., Amini, N., Coppens, D., Dejaeger, M., Dupont, J., de Vlam, K., Rossini, M., Viapiana, O., Laurent, M. R., & Adami, G. (2025) · Bone · doi:10.1016/j.bone.2025.117701 · Cited by 7
Macrophagic Sclerostin Loop2‐ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action
Wang, L., Tao, X., Zhang, N., Yang, X., Jiang, H., Li, X., Wang, S., Ding, S., Yu, S., Zhang, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202518735 · Cited by 7
Musculoskeletal Diseases: Mechanisms and Therapeutic Advances
Ma, X., Yinwang, E., Chai, X., Wang, F., Chen, Z., Wang, S., Zhou, H., Xue, Y., Lei, J., Chen, F., et al. (2025) · MedComm · doi:10.1002/mco2.70519 · Cited by 7
Sequential Versus Step-Therapy Approaches for Osteoporosis Management in Orthopedic Subspecialties
Salman, S. G., Phadke, R. A., Burnett, J., & Walsh, J. (2026) · Current Osteoporosis Reports · doi:10.1007/s11914-026-00967-0 · Cited by 7
Romosozumab for the treatment of postmenopausal women at high risk of fracture
Geusens, P., Appelman‐Dijkstra, N. M., Lems, W. F., & van den Bergh, J. P. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2152320 · Cited by 7
Risk factors associated with prognosis of patients with medication‐related osteonecrosis of the jaw
Tadokoro, Y., Hasegawa, T., Takeda, D., Murakami, A., Yatagai, N., Arimoro, S., Iwata, E., Saito, I., Kusumoto, J., & Akashi, M. (2023) · Head & Neck · doi:10.1002/hed.27574 · Cited by 7
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature
Mondo, I., Hannou, S., & D’Amelio, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2296543 · Cited by 8
Analysis of SIRT1 Gene SNPs and Clinical Characteristics in Medication-Related Osteonecrosis of the Jaw
Bojtor, B., Vaszilkó, M., Armos, R., Tóbiás, B., Podani, J., Szentpéteri, S., Balla, B., Lengyel, B., Pikó, H., Illés, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073646 · Cited by 7
Factors Impacting Fall Severity in Hospitalized Patients: A Retrospective Cohort Study
Liu, S., Yang, Y.-K., Kor, C., Sun, Y., Wang, H.-Y., Yang, Y., & Chou, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102827 · Cited by 7
Norisoboldine, a Natural Alkaloid from Lindera aggregata (Sims) Kosterm, Promotes Osteogenic Differentiation via S6K1 Signaling Pathway and Prevents Bone Loss in OVX Mice
Li, S., Yan, W., Sun, K., Miao, J., Liu, Z., Xu, J., Wang, X., Лі, Б., & Zhang, Q. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400193 · Cited by 7
Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019–2021
Soen, S., Wang, A. Y., Hamaya, E., Chien, H., & Lin, T. (2024) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-024-01530-6 · Cited by 7
Real-world effectiveness of osteoporosis screening in older Swedish women (SUPERB)
Zoulakis, M., Axelsson, K. F., Litsne, H., Johansson, L., & Lorentzon, M. (2024) · Bone · doi:10.1016/j.bone.2024.117204 · Cited by 7
Self-citation
Study protocol for the ROLEX-DUO randomised placebo-controlled trial: ROmosozumab Loaded with EXercise – DUal effects on bone and muscle in postmenopausal Osteoporosis and Osteopenia
Kumar, S., Beck, B. R., Nery, L., Byth, K., Elhindi, J., Wood, C., Fuller, O. K., Clifton-Bligh, R. J., & Girgis, C. M. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086708 · Cited by 9
LncRNA H19 promotes osteoclast differentiation by sponging miR-29c-3p to increase expression of cathepsin K
Li, H., Fu, Z., Tao, A., Wu, T., Zhan, X., Tang, H., Cui, X., Ma, Z., Li, C., Jiang, J., et al. (2024) · Bone · doi:10.1016/j.bone.2024.117340 · Cited by 7
Cost-effectiveness analysis of romosozumab for severe postmenopausal osteoporosis at very high risk of fracture in Mexico
Martinez, J. P. D., Maraumont, T. A.-D., Sánchez, E. N., Cordero, L. M. C., & Yeh, E. J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0299673 · Cited by 7
Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases
Everts‐Graber, J., Ferrari, S., Popp, A. W., Hars, M., Wenger, M., Oser, S., Studer, U., Steiner, C., Ziswiler, H., Schmid, G., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01598-1 · Cited by 7
Shuxuetong injection simultaneously ameliorates dexamethasone‑driven vascular calcification and osteoporosis
Xu, Z., Liu, X., Li, Y., Gao, H., He, T., Zhang, C., Hao, W., & Teng, X. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9630 · Cited by 7
New therapeutic options for bone diseases
Kocijan, R., Haschka, J., Feurstein, J., & Zwerina, J. (2021) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-020-00810-w · Cited by 7
The role of bone anabolic drugs in the management of periodontitis: a scoping review
Cecoro, G., Paoletta, M., Annunziata, M., Laino, L., Nastri, L., Gimigliano, F., Liguori, S., Toro, G., Moretti, A., Guida, L., et al. (2021) · European Cells and Materials · doi:10.22203/ecm.v041a20 · Cited by 7
Pros and Cons of Skeletal Medications in the COVID-19 Era
Tsourdi, E. A., & Drake, M. T. (2022) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-022-00192-7 · Cited by 7
Rational engineering of glycosaminoglycan-based Dickkopf-1 scavengers to improve bone regeneration
Ruiz‐Gómez, G., Salbach‐Hirsch, J., Dürig, J., Köhler, L., Balamurugan, K., Rother, S., Heidig, S.-L., Moeller, S. J., Schnabelrauch, M., Furesi, G., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122105 · Cited by 7
Anti‐Siglec ‐15 Antibody Prevents Marked Bone Loss after Acute Spinal Cord Injury‐Induced Immobilization in Rats
Peng, Y., Langermann, S., Kothari, P., Liu, L. L., Zhao, W., Hu, Y., Chen, Z., Perini, M. M. D. L., Li, J., Cao, J., et al. (2023) · JBMR Plus · doi:10.1002/jbm4.10825 · Cited by 7
Role of biophysical stimulation in multimodal management of vertebral compression fractures
Martino, A. C. D., Villari, E., Poluzzi, R., Brunello, M., Rossomando, V., D’Agostino, C., Ruta, F., & Faldini, C. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.11.023 · Cited by 7
Clinical characteristics, densitometric parameters and outcomes of patients with atypical femoral fractures related to bisphosphonate treatment for osteoporosis
Wong, C. H., Kan, A. K. C., Tsoi, K. H., Chan, S. S. Y., Jiang, N. S., Loong, C. H. N., Fong, C. H. Y., Wong, J. S. H., Shea, G. K., Cheung, C. L., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03608-z · Cited by 7
The role of sclerostin and dickkopf-1 in oral tissues – A review from the perspective of the dental disciplines
Samiei, M., Janjić, K., Cvikl, B., Moritz, A., & Agis, H. (2019) · F1000Research · doi:10.12688/f1000research.17801.1 · Cited by 7
Communicating Absolute Fracture Risk Reduction and the Acceptance of Treatment for Osteoporosis
Ralston, K. A. P., Phillips, J., Krause, A., Hauser, B., & Ralston, S. H. (2022) · Calcified Tissue International · doi:10.1007/s00223-022-00948-2 · Cited by 7
Identification and validation of novel gene markers of osteoporosis by weighted co expression analysis
Chen, Y., Zou, L., Lu, J., Hu, M., Yang, Z., & Sun, C. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-229 · Cited by 7
Musculoskeletal Health in Premature Ovarian Insufficiency. Part Two: Bone
Samad, N., Nguyen, H. H., Ebeling, P. R., & Milat, F. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1722849 · Cited by 7

Authors: Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
Affiliations: Inserm (FR)
Amgen (United States) (US)
ORCID: Saag, Kenneth G.
Petersen, Jeffrey
Brandi, Maria Luisa
Karaplis, Andrew C.
Lorentzon, Mattias
Thomas, Thierry
Maddox, Judy
Grauer, Andreas
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2017-10-12
Volume: 377
Issue: 15
Pages: 1417-1427
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1708322
OpenAlex: W2754720807
Cited by: 1,544
References: 31
Citations by year: 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
FWCI: 123.81
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Florence Research (University of Florence) (submittedVersion, other-oa)
Research Bank (Australian Catholic University) (submittedVersion)
Funders: Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
Gilead Sciences
Teva Pharmaceutical Industries
Radius Health
Medac
Chugai Pharmaceutical
Amgen Canada
UCB Pharma
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords: romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
MeSH terms: Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks